Status: Recruiting
A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer
This is a FiH phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of \[177Lu\]Lu-ABY-271 in subjects with HER2 positive metastatic breast cancer.
Participants needed: 21
Trial details
Phase: Phase 1Age: 18+Biological sex: FemaleType: InterventionalSponsor: AffibodyUpdated: Oct 1, 2025Locations: 3
Eligibility criteria
Subject has unresectable locally advanced or metastatic breast cancer [+6]
Active brain metastases [+2]